GK563

GK563 is a selective Ca2+-independent phospholipase A2 (GVIA iPLA2) inhibitor with an IC50 value of 1 nM. GK563 is 22000 times more active against GVIA iPLA2 than GIVA cPLA2. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes[1].

Product Specifications

CAS Number

[2351820-19-2]

UNSPSC

12352005

Target

Apoptosis; Phospholipase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gk563.html

Solubility

10 mM in DMSO

Smiles

CCC[C@H]1[C@@H](C(O1)=O)CCCCC2=CC=CC=C2

Molecular Formula

C16H22O2

Molecular Weight

246.34

References & Citations

[1]Dedaki C, et al. β-Lactones: A Novel Class of Ca2+-Independent Phospholipase A2 (Group VIA iPLA2) Inhibitors with the Ability To Inhibit β-Cell Apoptosis. J Med Chem. 2019 Mar 28;62 (6) :2916-2927.